NIH Pioneer Award Backs Scientist Building Cancer Therapies That Evolve Alongside Tumors

Leor Weinberger, a virologist and professor at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has received one of the most competitive honors in American biomedical science: the NIH Director’s Pioneer Award. The award, part of the National Institutes of Health’s High-Risk, High-Reward Research program, provides five years of funding to a small handful of investigators with outstanding records of creativity, and it will bankroll Weinberger’s most ambitious project yet: a cancer therapy designed to mutate and evolve over time, keeping pace with tumors that otherwise slip away from treatment. Remarkably, this is the second time Weinberger has earned the distinction, having first won the award in 2013 for work on an entirely different problem.

The therapeutic concept at the heart of the new grant is one that Weinberger calls a neoplasm emergent oncolytic virus, or neovirus, a name that nods both to the existing class of tumor-busting viruses that selectively infect cancer cells and, playfully, to the film The Matrix. Oncolytic viruses are not new in principle; researchers have long sought viruses that preferentially replicate inside and destroy malignant cells while sparing healthy tissue. What distinguishes the neovirus concept is its dynamism. Rather than deploying a fixed, static agent, the therapy is engineered to undergo its own evolutionary changes, so that as a tumor accumulates mutations to escape attack, the therapeutic agent can counter-adapt. The work is still at an early stage, but Weinberger’s laboratory has already demonstrated proof of concept for a therapy capable of evolving alongside a tumor.

Weinberger’s target diseases reflect the most stubborn failures of modern oncology: pancreatic cancer, glioblastoma, and acute myeloid leukemia. Each of these cancers carries devastating survival statistics, and each is driven in part by extraordinary genetic diversity within the tumor itself. That heterogeneity is precisely what makes them so dangerous. A conventional drug, however potent, applies uniform selective pressure across billions of malignant cells, and among that vast population there is almost always a subset carrying mutations that confer resistance. Those survivors repopulate the tumor, and the treatment that once worked becomes useless. It is a pattern that repeats across cancer medicine and that Weinberger regards as a fundamental flaw in how therapies are designed.

His critique of that flaw is deceptively simple. Cancers, like viruses, are dynamic, evolving biological systems, yet for more than a century medicine has attacked them with static, chemistry-based technologies. The insight first struck Weinberger as a young graduate student studying the biophysics of HIV, when he became consumed by what he saw as a fundamental mismatch between viruses and the therapies built to treat them. The rational solution, he concluded, was to build a therapy that could itself mutate, so that it could not be circumvented by mutation. Instead of the drug being outmaneuvered, the therapy would evolve together with its biological target, locked in a continuous chase.

The intellectual framework behind this idea comes from evolutionary biology, specifically the Red Queen Hypothesis, named for the character in Lewis Carroll’s Through the Looking-Glass who tells Alice that it takes all the running you can do to keep in the same place. In a co-evolutionary arms race, a pathogen continually counter-evolves even as its host evolves resistance and attempts to escape, leaving both parties running in place. Weinberger aims to impose that same dynamic on cancer. Rather than a tumor escaping a fixed drug, the therapy would run after the tumor as the tumor tries to run away, establishing a scenario in which neither side can gain a permanent advantage but the disease can no longer simply outpace treatment.

The road to this point has been long and littered with failure. For more than twenty years, Weinberger recalls, colleagues dismissed the idea in polite and sophisticated ways, telling him the concept did not exist, that he would not find it, and that he should stop working on it. When he won his first Pioneer Award in 2013, he spent years engineering roughly 150,000 therapeutic candidates, and every one of them failed. The turning point came unexpectedly: a postdoctoral researcher in his lab brought him an image of the amputated genetic material the team had pursued for two decades, and it had evolved by itself in a flask at the back of the laboratory. That accidental foothold led to pre-clinical trials that behaved exactly as Weinberger had imagined twenty years earlier, protecting cells from HIV infection.

That HIV therapy is now in the final stages of FDA review for clinical trials, and the concept has already proven adaptable. In 2020, Weinberger’s team produced a COVID-19 therapeutic candidate based on the same evolutionary principles in roughly eighteen months. That speed matters for the cancer pivot. Because the group now has a working precedent for a therapeutic that can track the rapid evolution of HIV, Weinberger believes the transition to oncology can proceed far faster than the decades the original concept required. The same design logic, he argues, can be used to rapidly build a new class of therapeutics across multiple domains of medicine, including the deadliest cancers.

To carry the work from laboratory to patients, Weinberger moved to the Miller School in 2025, drawn by its Phase 1 clinical trial unit for experimental therapeutics. He describes Sylvester as a place designed to propel therapeutic concepts into the clinic, and he notes that clinical colleagues there have indicated that when the medical need is dire enough, they are prepared to move directly to testing in patients rather than delay a potentially life-saving medicine. That bench-to-bedside integration is paired with a demographic reality: the region’s rapidly expanding aging population represents the dominant risk factor for cancer, placing the new therapy’s potential patient population close at hand.

The stakes of the project are matched by its uncertainty, and Weinberger is candid about both. He acknowledges that it is not perfectly sane to follow an idea for decades while it keeps failing, but he argues that when success means a medicine that could help millions of people, persistence is the only reasonable course. If the reward is significant enough, he says, for example overcoming pancreatic cancer, it is worth the possibility of failure. With the Pioneer Award now funding the effort, an evolving-therapy precedent already validated against HIV, and a clinical infrastructure built for experimental treatments, Weinberger and his team are positioned to test whether the Red Queen can finally be made to run on the side of medicine, chasing tumors that have always, until now, run faster.

Subject of Research: Development of an evolving oncolytic virus cancer therapy to counter tumor mutation-driven drug resistance

Article Title: NIH honors Sylvester scientist developing cancer therapy that can evolve to outsmart tumors

Article References: NIH honors Sylvester scientist developing cancer therapy that can evolve to outsmart tumors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NIH Director's Pioneer Award, Leor Weinberger, oncolytic virus, cancer therapy, drug resistance, tumor evolution, pancreatic cancer, glioblastoma, acute myeloid leukemia, Red Queen Hypothesis, Sylvester Comprehensive Cancer Center, High-Risk High-Reward Research